newsLBPs may offer hope to IBS patients in the near future, says report2 August 2021 | By Anna Begley (European Pharmaceutical Review)Live biotherapeutic products (LBPs) are expected to help patients with IBS who currently have no US- or EMA-approved treatments.
news2021 a pivotal year for personalised neoantigens, says GlobalData21 July 2021 | By Anna Begley (European Pharmaceutical Review)With multiple catalysts coming up in late 2021, GlobalData reports a boom in the field of personalised neoantigen immuno-oncology therapeutics.
newsAI and big data will continue to disrupt pharma sector, says survey19 July 2021 | By Anna Begley (European Pharmaceutical Review)A GlobalData report has revealed the extent to which companies will be using AI and big data in drug discovery and development processes.
newsChinese patent reforms to bolster pharma innovation17 June 2021 | By Hannah Balfour (European Pharmaceutical Review)Market research suggests the new drug patent reforms in China, in addition to other regulatory changes, will incentivise innovative pharma research.
newsAlzheimer’s drug Aduhelm™ authorised in US under accelerated approval8 June 2021 | By Hannah Balfour (European Pharmaceutical Review)Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s since 2003 and the first therapy to target the fundamental pathophysiology of the disease – amyloid plaques.
newsCompetition and Markets Authority investigating AstraZeneca’s Alexion acquisition28 May 2021 | By Hannah Balfour (European Pharmaceutical Review)The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
newsIndustry hustling to ensure supply of recombinant vector COVID-19 vaccines25 May 2021 | By Hannah Balfour (European Pharmaceutical Review)A new report suggests pharma is working hard to combat worldwide viral vectors shortage that could threaten the COVID-19 vaccine rollout.
newsCMOs should invest in biologic API manufacturing capabilities, says GlobalData13 May 2021 | By Hannah Balfour (European Pharmaceutical Review)Research shows the complexity and number of biologics is increasing, as is the frequency at which their active pharmaceutical ingredient (API) production is outsourced.
newsCOVID-19 manufacturing requirements are lucrative for CMOs, says GlobalData30 April 2021 | By Hannah Balfour (European Pharmaceutical Review)A new report shows half the drugs and all the vaccines approved for emergency use in 2020 had an associated contract manufacturing agreement.
newsCould viral vector shortages disrupt the COVID-19 vaccine roll-out?25 March 2021 | By Hannah Balfour (European Pharmaceutical Review)According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
newsCRISPR therapies could be one of the most transformative in human history, says GlobalData16 March 2021 | By Hannah Balfour (European Pharmaceutical Review)Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
articleDiabetes and obesity: treatment and trials update8 March 2021 | By Hannah Balfour (European Pharmaceutical Review)European Pharmaceutical Review reports on some of the latest developments in treatments for type 2 diabetes and obesity.
newsLaunch of generic oncology medications to improve treatment access in India2 March 2021 | By Hannah Balfour (European Pharmaceutical Review)GlobalData suggests the recent approval of new generics in oncology should enhance access and adherence to cancer treatment by reducing costs borne by patients.
articleCOVID’s impact on cancer therapeutics: clinical trial and treatment disruptions19 February 2021 | By Hannah Balfour (European Pharmaceutical Review)In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
newsDisinformation and safety concerns could prevent successful COVID-19 vaccination campaigns12 February 2021 | By Hannah Balfour (European Pharmaceutical Review)Research suggests at least a fifth of the US population are resistant to receiving a COVID-19 vaccine, reports suggest this could be due to disinformation and safety concerns.
